Alpha Modus (AMOD) Chief Executive William Alessi emphasized Thursday the company's "strong" fundamentals and an "ongoing" growth strategy amid "uninformed speculation" by certain market participants.
"The recent sell-side activity targeting AMOD stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy coupled with the 'de-SPAC norm,'" Alessi said in a company statement.
Shares soared 133% as intraday trading volume surged to over 115.9 million from a daily average of about 66,000.
Tectonic Therapeutic (TECX) shares surged 109% after the company said Thursday a phase 1b trial showed that a single intravenous dose of TX45 resulted in "meaningful improvements" in left ventricular function and pulmonary hemodynamics.
Over 4.3 million shares traded intraday versus a daily average of nearly 144,000.
Alterity Therapeutics (ATHE) said Thursday its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.
Shares jumped 50% as intraday trading volume catapulted to more than 20.6 million from a daily average of about 71,000.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。